The Oncologist Who Made Advanced Cancer Care Affordable: The Story of Dr. Lalit Kumar

In the busy wards of India’s premier medical institutes, one doctor spent decades fighting cancer not only with the latest science but with a deep concern for cost and accessibility. Dr. Lalit Kumar, a medical oncologist, became known for bringing complex treatments like bone marrow and stem cell transplantation within reach of ordinary patients.

He graduated in medicine and completed his MD from Sarojini Naidu Medical College in Agra. He then specialised with a DM in Medical Oncology at the Adyar Cancer Institute in Chennai. Further training took him to the Royal Postgraduate Medical School at Hammersmith Hospital in London for a post-doctoral fellowship, and he later held a Fulbright Scholarship in the United States.

At the All India Institute of Medical Sciences (AIIMS) in New Delhi, he rose to become Professor and Head of the Department of Medical Oncology at the Dr. B.R. Ambedkar Institute Rotary Cancer Hospital. There he focused on multiple myeloma, other haematological malignancies, and gynaecological cancers. One of his most important contributions was developing cost-effective protocols for sustained bone marrow and stem cell transplantation—protocols that helped more patients receive life-saving treatment without the burden of prohibitive expenses.

After a long and distinguished tenure at AIIMS, he continued his work as Chairperson of Oncology and Bone Marrow Transplantation at Artemis Hospital in Gurugram, remaining a leading voice in the field.

In 2008 the Government of India honoured him with the Dr. B.C. Roy Award, the highest recognition for medical professionals. In 2014 he received the Padma Shri for his contributions to medicine. He has also been recognised with the ICMR Award, the Ranbaxy Science Foundation Award, and fellowships from the Indian Academy of Sciences and the National Academy of Medical Sciences.

One afternoon, after reviewing the progress of a patient who had undergone a transplant, a young resident asked him, “Sir, why put so much effort into making these complex treatments cheaper when the science itself is already so demanding?”

Dr. Lalit Kumar looked up and answered simply.

“Cancer cells grow every day and very fast. Loss of even a day is a great loss for the patient. But if the treatment is so expensive that most people cannot afford it, then the science remains incomplete. Our real success is when a patient who could not have hoped for a transplant walks out cured—and when that becomes possible for many more families, not just a few.”

And so the oncologist from Agra who trained in Chennai, London and the United States continues to be remembered for advancing both the science of cancer care and the principle that advanced treatment must also be accessible—turning complex protocols into practical hope for patients across India.

Dr. Lalit Kumar’s Cost-Effective Protocols for Bone Marrow and Stem Cell Transplantation

Dr. Lalit Kumar, the Padma Shri-awarded medical oncologist (formerly Professor and Head of Medical Oncology at AIIMS, New Delhi, and later Chairperson of Oncology & BMT at Artemis Hospitals), is widely recognised for his leadership in developing cost-effective treatment protocols for bone marrow transplantation (BMT) and haematopoietic stem cell transplantation (HSCT). These efforts focused on making advanced, potentially curative therapies accessible to a larger number of Indian patients, particularly those with multiple myeloma, other haematological malignancies, and certain solid tumours.

Core Contributions

During his long tenure at the Dr. B.R. Ambedkar Institute Rotary Cancer Hospital (AIIMS), Dr. Kumar helped establish and refine a sustained BMT/stem cell transplant programme. The emphasis was on:

• Protocol-based, standardised care — Clear guidelines for patient selection, conditioning regimens, stem-cell mobilisation and harvest, supportive care, and post-transplant monitoring. This reduced variability, complications, and unnecessary costs.
• Optimising resource use in a public-hospital setting — Leveraging generic chemotherapeutic drugs, efficient hospitalisation, trained manpower, and rigorous follow-up to keep expenses significantly lower than in Western countries or many private Indian centres.
• Focus on high-impact diseases — Especially autologous HSCT for multiple myeloma (where transplant can prolong remission) and allogeneic transplants for other blood cancers/leukaemias, while carefully identifying high-risk patients who would benefit most.

Cost Impact (Illustrative Figures from Public Sources)

Costs vary by type of transplant, patient condition, and hospital setting, but Dr. Kumar and related AIIMS data have consistently highlighted affordability:

• In earlier years (around 2013), autologous transplant at AIIMS was reported at under ₹3 lakhs (approximately US$6,000 at the time).
• More recent estimates associated with the Indian context (including comments by Dr. Kumar) place:
  • Autologous HSCT at around ₹7 lakhs.
  • Allogeneic (matched sibling) at around ₹15 lakhs.
  • Haploidentical at around ₹25 lakhs.

These figures remain substantially lower than equivalent procedures in North America or Western Europe, largely due to the use of generics, lower hospitalisation and professional fees, and streamlined protocols. In government or charitable settings the costs can be even more restrained, with additional support available through schemes such as Rashtriya Arogya Nidhi for eligible patients.

Clinical and Systemic Approach

The “cost-effective protocols” were not a single proprietary recipe but a comprehensive framework that included:

• Careful case selection and risk stratification.
• Use of established, evidence-based conditioning and mobilisation regimens adapted to local realities.
• Strong supportive care to minimise infections and other complications (a major cost driver).
• Emphasis on measurable residual disease monitoring and timely interventions where appropriate.
• Training of physicians, nurses and technical staff to sustain quality at scale.

Dr. Kumar has also contributed to national discussions and guidelines on haematopoietic cell transplantation and has published extensively on outcomes of autologous stem-cell transplantation in multiple myeloma, reinforcing that well-executed, protocol-driven care can deliver good results at lower cost.

In short, his work helped demonstrate that high-quality BMT/stem-cell transplantation is feasible and sustainable in the Indian public-health context when protocols prioritise both clinical excellence and economic accessibility. This approach has influenced practice beyond AIIMS and continues to guide efforts to expand transplant capacity across the country.